(CPI) is pleased to announce a collaboration with Bausch + Lomb to leverage CPI's artificial intelligence (AI) machine learning tools and expertise to identify new drugs for eye diseases.
We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Bausch + Lomb Corporation (NYSE:BLCO) stands against the other best ...
Over the last year, CPI has been working with Bausch + Lomb on multiple preclinical and clinical drug discovery projects using its AI technologies. These include efforts to identify new drug ...
"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et ...
Health scientists from the University of Virginia have found a previously unknown contributor to harmful blood vessel growth ...
The global vision care products market is projected to reach USD 103.7 billion by 2032, growing at a CAGR of 6.21%. This growth ...
Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...
City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...
City Therapeutics and Bausch + Lomb have entered into a strategic collaboration focused on the development of an RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback